<code id='382B696A67'></code><style id='382B696A67'></style>
    • <acronym id='382B696A67'></acronym>
      <center id='382B696A67'><center id='382B696A67'><tfoot id='382B696A67'></tfoot></center><abbr id='382B696A67'><dir id='382B696A67'><tfoot id='382B696A67'></tfoot><noframes id='382B696A67'>

    • <optgroup id='382B696A67'><strike id='382B696A67'><sup id='382B696A67'></sup></strike><code id='382B696A67'></code></optgroup>
        1. <b id='382B696A67'><label id='382B696A67'><select id='382B696A67'><dt id='382B696A67'><span id='382B696A67'></span></dt></select></label></b><u id='382B696A67'></u>
          <i id='382B696A67'><strike id='382B696A67'><tt id='382B696A67'><pre id='382B696A67'></pre></tt></strike></i>

          focus

          focus

          author:leisure time    Page View:4
          Abbott's heart device TriClip on a gradient dark blue background — coverage from STAT
          The device is called the TriClip, and it addresses a disease called tricuspid regurgitation: a heart condition that causes blood to leak backward through the tricuspid heart valve. Illustration: STAT; Photo: Courtesy Abbott

          An advisory panel to the Food and Drug Administration voted in favor of a new device from Abbott meant to treat patients with tricuspid heart valve disease. All but one of the 14 panelists said the treatment’s benefits outweighed its risks. The FDA tends to follow advisory panel recommendations.

          “If we can help symptoms with this at a low cost in terms of risk, I think it makes a lot of sense,” said James Blankenship, a panelist and cardiologist at the University of New Mexico. 

          advertisement

          The device is called the TriClip, and it addresses a disease called tricuspid regurgitation: a heart condition that causes blood to leak backward through the tricuspid heart valve. The condition impacts 1.6 million people in the United States. Symptoms include fatigue, swelling, and atypical heart rhythms. In severe cases, the condition can lead to heart failure. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          Anthos stroke drug appears safer than common blood thinner
          Anthos stroke drug appears safer than common blood thinner

          AdobePHILADELPHIA—Aninvestigationaldrugaimedatpreventingstrokessignificantlyreducedtheriskofbleeding

          read more
          Hollywood unions extend contract negotiations for actors
          Hollywood unions extend contract negotiations for actors

          1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

          read more

          Physician subsidies by hospitals soar in wake of No Surprises Act

          AdobePhysicianstaffingfirms,flailinginthewakeofafederallawbanningsurprisebills,aredemandingextrapaym